Sionna Therapeutics, Inc. (NASDAQ:SION - Get Free Report) gapped down before the market opened on Tuesday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $12.90, but opened at $12.43. Sionna Therapeutics shares last traded at $12.43, with a volume of 779 shares trading hands.
The company reported ($0.62) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.17).
Analyst Ratings Changes
Several research firms recently commented on SION. Stifel Nicolaus began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $32.00 price objective on the stock. TD Cowen began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating on the stock. Finally, Guggenheim began coverage on shares of Sionna Therapeutics in a research note on Tuesday, March 4th. They set a "buy" rating and a $45.00 price objective on the stock.
Get Our Latest Research Report on SION
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. bought a new position in shares of Sionna Therapeutics in the first quarter worth approximately $109,258,000. TPG GP A LLC bought a new position in shares of Sionna Therapeutics in the first quarter worth approximately $69,925,000. Atlas Venture Life Science Advisors LLC bought a new position in shares of Sionna Therapeutics in the first quarter worth approximately $38,639,000. Jennison Associates LLC bought a new position in shares of Sionna Therapeutics in the first quarter worth approximately $8,995,000. Finally, Aberdeen Group plc bought a new position in shares of Sionna Therapeutics in the first quarter worth approximately $7,803,000.
Sionna Therapeutics Stock Performance
The company has a 50 day moving average of $11.95.
Sionna Therapeutics Company Profile
(
Get Free Report)
We are a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (“CF”) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (“CFTR”) protein to deliver clinically meaningful benefit to CF patients.
See Also
Before you consider Sionna Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sionna Therapeutics wasn't on the list.
While Sionna Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
